Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (CYNK001GBM01)
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)
Sponsor: Celularity Incorporated
Terminated
Business decision.
Other terminated trials from Celularity Incorporated
A PHASE1 clinical study on Analgesics and Analgesics, Non-narcotic, this trial is terminated or withdrawn. The trial is conducted by Celularity Incorporated and has accumulated 11 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Terminated PHASE1
-
Feb 2022 — Jun 2022 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 6 earlier versions
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celularity Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .